Anti-Human DEspR Recombinant Antibody (7C5B2) (CAT#: TAB-190MZ)

Figure 1 shows displacement of fluorescently labeled 7C5B2 binding to Panel CSCs by different peptide ligands.

50,000 cells were reacted with 10 μg/ml AF568-labelled 7C5B2 monoclonal antibody (mAb) at 4° C. for 20 min in the absence or presence of the different peptides at 100× molar excess. Samples were immediately subjected to FACS analysis for quantification of DEspR+ cells. Samples were run in duplicates. AngII, angiotensinII; ET1, endothelin-1 (DEspR ligand); sp17, VEGFsp17 (DEspR ligand); sp26, VEGFsp26 (DEspR ligand). Data presented as Mean±SD.

Figure 2 shows testing of 5G12E8, 7C5B2 and 6G8G7 anti-hDEspR monoclonal antibodies (mAbs) on CSC-growth.

2,000 CSCs were seeded in 200 μL of complete MammoCult media in an ultra-low attachment 96-well plate. Cells were either not treated (control) or treated with mAbs (200 μg/ml) at days 0, 2 and 4. Live cells were counted using Trypan Blue at day 5. Each experiment was run in five replicates. Data is presented as Mean±SEM. ***P<0.001

Figure 3 shows in vitro inhibition of CSC growth by vh3/vk2 (vh3), vh5/vk1 (vh5), 6G8G7 and 7C5B2 mAbs.

2000 CSCs were seeded in 200 μL of complete MammoCult media in an ultralow attachment 96-well plate in absence (control) or presence (treated) of 100 μg/ml (7C5B2, 6G8G7), 300 μg/ml (vh5/vk1) and 450 μg/ml (vh3/vk2) of corresponding monoclonal antibodies (mAbs). Cells were treated at days 0, 2 and 4. After 5 days in culture live cells were counted using Trypan Blue. Each condition was performed in six replicates. Data is presented as Mean±SEM. ***, P<0.001

Figure 4 shows inhibition of Panel, MB231 dependent in vivo tumour initiation by 7C5B2 and vh5/vk1 monoclonal antibodies (mAbs).

Figure 5 shows anti-hDEspR monoclonal antibody (mAb) decreases tumor progression, and increases survival: pancreatic peritoneal metastasis nude rat model.

mAb dose: 1 mg/kg ip; One Way ANOVA followed by Holm Sidak Multiple Comparisons Test: p=0.002 (7C5B2 vs saline); p=0.0002 (6g8g7 vs Saline); Gemcitabine (max dose: 26 mg/kg×4) vs saline: not significant.

Figure 1 Anti-Human DEspR Recombinant Antibody (TAB-190MZ) in SDS-PAGE

Lane 1: Non-reduced
Lane 2: Reduced

Figure 2 Anti-Human DEspR Recombinant Antibody (TAB-190MZ) in HPLC

The purity of TAB-190MZ was greater than 95% as determined by SEC-HPLC.